DiD Articles

Despite clinical acceptance of the efficacy of long-acting injectables (LAIs) to provide prolonged stability for people suffering from schizophrenia, they still only make up about 13% of the market. Psychiatrists continue to prescribe daily orals, often citing patient acceptance as a major barrier. This fuels a cycle of oral nonadherence that often leads to relapse and loss. ​